Skip to main content

Table 2 Summary of common recurrently amplified regionsa, b

From: Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

Cytogenetic region Mb start position (BAC) Mb end position (BAC) Size (Mb) Genesc No. cases
1p34 39.27 (RP11-528I12) 40.26 (RP11-747C18) 1.0 MACF1, PABPC4, TRIT1 3 (8%)
1q23 157.00 (RP11-735D24) 157.81 (RP11-812N5) 0.8 - 4 (11%)
2p25 9.42 (RP11-360P14) 10.34 (RP11-360P14) 0.9   3 (8%)
3p25 10.20 (RP13-635L13) 12.52 (RP11-738A2) 2.3 TATDN2, SEC13L1, VGLL4 3 (8%)
6p22 20.07 (RP11-345F7) 22.08 (RP11-630B10) 1.8   8 (21%)
8q22 101.23 (RP11-321E7) 102.99 (RP11-811I18) 1.8   5 (13%)
10q22 76.24 (RP11-368I19) 78.49 (RP11-272P2) 2.3 MYST4 3 (8%)
11q13 69.07 (CTD-2192B11) 70.20 (CTD-2011L13) 1.1 CCND1, ORAOV1, PPFIA1, CTTN 3 (8%)
16p13 10.59 (RP11-78D17) 12.84 (RP11-310B24) 2.3 NUBP1, DEXI, TXNDC11, ZC3H7A, RSL1D1, GSPT1 3 (8%)
  1. aMapping data is based on the UCSC genome browser (May 2004 freeze), and listed regions represent core amplicons.
  2. bOnly regions amplified in at least 3 cases are listed.
  3. cGenes that showed top ranking expression levels when genomically amplified. More detailed data for the 6p22, 8q22, and for 2p25 is given in Additional file 3.